Cisplatin and 5-FU +/- Panitumumab for Patients With Nonresectable,Advanced or Metastatic Esophageal Squamous Cell Cancer (POWER)
An Open-label, Randomized Phase III Trial of Cisplatin and 5-fluorouracil With or Without Panitumumab for Patients With Nonresectable, Advanced or Metastatic Esophageal Squamous Cell Cancer
Sponsor: AIO-Studien-gGmbH
Terminated
Sponsor decision due to recommendation of the IDMC.
Other terminated trials from AIO-Studien-gGmbH
Listed as NCT01627379, this PHASE3 trial focuses on Esophageal Squamous Cell Cancer and remains terminated or withdrawn. Sponsored by AIO-Studien-gGmbH, it has been updated 6 times since 2012, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
6 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE3
-
Jan 2021 — Jul 2024 [monthly]
Terminated PHASE3
-
Jun 2018 — Jan 2021 [monthly]
Terminated PHASE3
-
Mar 2018 — Jun 2018 [monthly]
Terminated PHASE3
Status: Active Not Recruiting → Terminated
▶ Show 1 earlier version
-
Jan 2017 — Mar 2018 [monthly]
Active Not Recruiting PHASE3
First recorded
May 2012
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- AIO-Studien-gGmbH
- Amgen
- Assign Clinical Research GmbH
- Assign Data Management and Biostatistics GmbH
For direct contact, visit the study record on ClinicalTrials.gov .